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1. Introduction
EGCG is the major component of catechins found in green 
tea and exists in four active forms: (1)-epigallocatechin-
3-gallate (EGCG), (2)-epigallocatechin (EGC), 
(3)-epicatechin-3-gallate (ECG), and (4)-epicatechin (EC) 
(Zeng et al., 2014). Catechins, which are polyphenols, 
constitute nearly 30%–40% of the dry weight of green tea 
(Lecumberri et al., 2013; Zeng et al., 2014), which is one 
of the most popular beverages in the world, after water. 
EGCG is an important compound, as it has antitumor 
activity. It exerts this activity by binding to the active 
center of DNA methyltransferase-1 (DNMT1) enzyme, as 
previously demonstrated by in vitro activity assays (Lee et 
al., 2005; Pandey et al., 2010). Thus, it is involved in the 
changes in gene expression by an epigenetic mechanism 
decreasing DNA hypermethylation and is a potential 
anticancer drug for cancer prevention or treatment (Fang 
et al., 2003; Chen et al., 2011). 
Cancer development and progression is a multistep 
process evolving through both genetic and epigenetic 
mechanisms. The loss of function of tumor suppressor 
genes is a fundamental step that is quite well known in 
cancer development. Aberrant promoter methylation, 
especially hypermethylation of tumor suppressor genes, is 
an important mechanism of epigenetic silencing (Baylin 
and Herman, 2000; Brooks, 2009; Nystrom and Mutanen, 
2009; Arends, 2013). Nearly half of all known tumor 
suppressor genes might be inactivated by hypermethylation 
(Arai et al., 2006).
Breast and colorectal cancers are common cancers and 
constitute a major public health problem; thus, they are 
important targets for research and the implementation of 
treatment (Cho et al., 2010; Colussi et al., 2013). It has been 
reported that CpG island methylation of tumor-related 
genes is an important event in both the pre-invasive and 
progression stages of breast cancer (Park et al., 2011). 
Colorectal cancer is another common cause of morbidity 
and mortality, and dietary components play an important 
role in the pathogenesis and, therefore, prevention of this 
cancer (Singh and Fraser, 1998). In recent years, specific 
nutritional components, such as catechins, have been 
reported to be bioactive molecules acting on cancer cells 
(Fang et al., 2003; Li and Tollefsbol, 2010; Nandakumar et 
al., 2011). 
In this study, considering (1) EGCG is a potential 
anticancer drug, (2) it binds to DNA methyltransferase 
enzyme, (3) promoter methylation of tumor suppressor 
genes is an important mechanism of epigenetic 
silencing, and (4) epigenetic silencing is important to the 
carcinogenesis of adenocarcinomas, we aimed to evaluate 
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the effects of EGCG on the methylation status of 25 tumor 
suppressor gene promoters in colorectal (HT-29) and 
breast cancer (MCF-7) cell lines. Methylation-specific 
multiplex ligation probe amplification (MS-MLPA) was 
used for the analysis that determines both the methylation 
status of genes of interest and the copy number changes. 
We tested the effects of different EGCG concentrations on 
the methylation status of tumor suppressor gene promoters 
in HT-29 and MCF-7 cell lines and also assayed effects of 
these application concentrations on cell proliferation.
2. Materials and methods
2.1. Cell lines
Human colon adenocarcinoma (designation: HT-29, ATCC 
number: HTB-38) and human breast adenocarcinoma 
(designation: MCF-7, ATCC number: HTB-22) cell lines 
were obtained from the American Type Tissue Culture 
Collection (ATCC). Cells were cultured in RPMI 1640 
supplemented with 10% fetal bovine serum, 2 mM 
L-glutamine, penicillin (100 IU/mL), and streptomycin 
(100 μg/mL) (media and serums from Biochrom AG, 
Berlin, Germany). All cells were cultured at 37 °C in the 
humidified atmosphere of a 5% CO2 incubator (Heraeus, 
Hanau, Germany).
2.2. EGCG treatment
Commercially available (−)-epigallocatechin gallate was 
used in the experiments (Sigma-Aldrich, St Louis, MO, 
USA). Powdered EGCG was dissolved in water to prepare 
5 mg/mL stock solution and stored at –20 °C. For each cell 
line (MCF-7 and HT-29), 2 million cells were transferred 
to 9 different 25 cm2 tissue culture flasks. Three of these 
flasks were assigned as the control group, and EGCG was 
not applied to these flasks. The other 6 flasks were used in 
duplicate for EGCG application. HT-29 and MCF-7 cells 
were incubated with 10 µM, 20 µM, and 50 µM (Zhang, 
2012) and 1 µM, 5 µM, and 10 µM (Lee et al., 2005; Hsu 
et al., 2011) EGCG, respectively for 48 h, as defined by 
previous studies. At the end of 48 h for all groups, DNA 
samples were extracted from both untreated control 
cells and EGCG-treated cells by using QIAamp DNA 
mini kit (Qiagen, Carlsbad, Germany), according to the 
manufacturer’s instructions.
2.3. MS-MLPA analysis
SALSA MLPA kit ME002-B1 Tumor Suppressor 2 kit 
(MRC Holland, Amsterdam, the Netherlands) was 
utilized to analyze the methylation status of promoter 
regions of 25 different tumor suppressor genes (Table). 
MLPA reactions were performed according to the 
manufacturer’s instructions. Briefly, 250 ng of genomic 
DNA extracted from control and EGCG applied cell 
lines in 5 µL of TE buffer (10 mM Tris-HCl, pH 8.2; 0.1 
mM EDTA) was denatured. Oligonucleotide probes were 
hybridized to the genomic DNA for 16 h. Following the 
hybridization reaction, hybridized probes were ligated 
via ligation reaction. All reaction tubes were divided into 
two tubes, one for copy number analyses and the second 
for methylation analyses. To determine the methylation 
status of the promoter regions, a restriction endonuclease 
reaction was performed by using HhaI enzyme. As a 
methylation-sensitive restriction endonuclease, HhaI can 
only digest an unmethylated DNA target. Following HhaI 
digestion, PCR reaction was performed in all tubes. PCR 
products were denatured and loaded onto an ABI 3500 
capillary electrophoresis system (Applied Biosystems, 
Foster City, CA, USA). Band analysis was performed 
by GeneMapper software (Applied Biosystems), and 
Coffalyser Net program (MRC Holland) was used to 
determine copy number analysis and methylation status of 
the EGCG-treated and untreated samples. The assay uses 
14 reference probes (Figures 1 and 2; last 14 data points). 
The undigested PCR runs were analyzed to obtain the copy 
number ratio in samples. The ratios were calculated by 
dividing the peak area obtained from each PCR reaction 
by the sum of the area of reference probes (Figures 1A and 
2A). Fragment analysis of digested samples was performed 
to determine unmethylated regions. Since reference probes 
do not have HhaI restriction sites, the total of peak area 
values obtained from reference probes served as controls 
to methylated regions that were not digested by the 
enzyme. The methylation ratio was obtained by dividing 
each digested probe’s peak area by the sum of the area of 
reference probe peaks (Figures 1B and 2B). Differences in 
methylation status between EGCG-treated and untreated 
cells were compared using independent samples t-test. 
SPSS version 20.0 (IBM Corp., Armonk, NY, USA) was 
used for statistical analysis, and P < 0.05 was considered 
significant. 
2.4. Assay for cell proliferation
The effects of EGCG application on the proliferation 
of MCF-7 and HT-29 cells were colorimetrically tested 
by biochemical reduction of MTT (3-(4,5-dimethyl-2-
thiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) 
(Sigma-Aldrich). Briefly, EGCG was serially diluted in half 
from 400 to 1 µM in 96-well microtiter plate rows, except 
for the untreated cells and medium control wells. Plates 
were incubated for 48 h. The inhibition of cell proliferation 
was determined after 4 h of incubation with 20 µL of MTT 
(5 mg/mL). The optical density of the sodium dodecyl 
sulfate (10%) (Sigma-Aldrich) solubilized tetrazolium salt 
was measured at 540 nm with an ELISA reader (Biotek 
Instrument ELx800, Winooski, VT, USA). Inhibition of 
cell proliferation and inhibitory concentration 50 (IC50) 
values (EGCG concentrations at which 50% of cells are 
viable) were calculated from the logarithmic trend lines 
of the proliferation versus EGCG concentration graphs. 
Data of the triplicate experiments are expressed as mean ± 
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standard error of means (SE). Differences in IC50 between 
cell lines were statistically evaluated by independent 
samples t-test at the 0.05 level using SPSS version 20.0 
(IBM Corp., USA).
3. Results
3.1. Effects of EGCG on the methylation status of tumor 
suppressor genes in MCF-7 and HT-29
Copy number analysis of the undigested (Figures 1A and 
1B) MCF-7 and HT-29 samples demonstrated that 25 
tumor suppressor genes (Table) had neither duplications 
nor deletions in their promoter regions. Similarly, there 
were no changes in the copy numbers of the EGCG-treated 
samples. Methylation status of the promoter regions of 25 
tumor suppressor genes was detected by fragment analysis 
of HhaI-digested samples. Each digested probe’s peak area 
was divided by the combined peak areas of the control 
probes lacking a HhaI restriction site, and methylation 
ratios were obtained (Figures 1B and 2B). Accordingly, 
promoter regions of CDH13, GATA5, and RARβ genes 
were found to be hypermethylated in all samples from the 
MCF-7 cell line, either EGCG-treated or untreated (Figure 
Table. List of the tumor suppressor genes in which the methylation status of promoter regions was analyzed. Genes are listed according 
to their chromosomal locations and nominated using the Universal Protein Resource (UniProt) catalog of information on proteins 
(http://www.uniprot.org). 
UniProt number Gene alias Gene name Chromosomal location
Q15350 TP73 Tumor protein p73 1p36.32
P52701 MSH6 DNA mismatch repair protein 2p16.3
P10826 RARB Retinoic acid receptor beta 3p24.2
P40337 VHL Von Hippel–Lindau disease tumor suppressor 3p25.3
P03372 ESR1 Estrogen receptor 6q25.1
Q02548 PAX5 Paired box protein 9p13.2
P42771 CDKN2A Cyclin-dependent kinase inhibitor 2A 9p21.3
B2CW77 KLLN Killin 10q23.31
P16455 MGMT Methylated-DNA--protein-cysteine methyltransferase 10q26.3
P16070 CD44 CD44 antigen 11p13
P26367 PAX6 Paired box protein 11p13
P19544 WT1 Wilms tumor protein 11p13
P09211 GSTP1 Glutathione S-transferase P 11q13.2
Q13315 ATM Serine-protein kinase 11q22.3
Q9BY67 CADM1 Cell adhesion molecule 1 11q23.3
Q96EP1 CHFR E3 ubiquitin-protein ligase 12q24.33
P51587 BRCA2 Breast cancer type 2 susceptibility protein 13q13.1
P06400 RB1 Retinoblastoma-associated protein 13q14.2
P07996 THBS1 Thrombospondin-1 15q14
Q9ULZ3 PYCARD Apoptosis-associated speck-like protein containing a CARD 16p11.2
R55290 CDH13 Cadherin-13 16q23.3
P38398 BRCA1 Breast cancer type 1 susceptibility protein 17q21.31
P04637 TP53 Cellular tumor antigen p53 17p13.1
Q15831 STK11 Serine/threonine-protein kinase 19p13.3
Q9BWX5 GATA5 Transcription factor 20q13.33
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1B). However, we did not detect a statistically significant 
difference between treated and untreated groups. RARβ, 
ESR1, PAX6, WT1, CADM1, CHFR, CDH13, and GATA5 
genes were hypermethylated in the HT-29 cell line in 
addition to these three genes (Figure 2B). However, we did 
not detect changes in methylation status in our samples in 
HT-29 after EGCG application.
3.2. Antiproliferative effects of EGCG on MCF-7 and 
HT-29 cells
MTT analysis revealed a concentration-dependent growth 
inhibition by EGCG in both cell lines (Figure 3). IC50 was 
11.2 ± 1.4 µM for MCF-7 cells, whereas it was 136.3 ± 2.1 
µM for HT-29 cells. MTT results demonstrated that EGCG 
caused significantly (P < 0.05) higher cytotoxicity in MCF-
7 cells compared to HT-29 cells. Next, we calculated 
the effect of application concentrations on cell viability. 
Viability of MCF-7 cells was 91.5 ± 1%, 65.3 ± 3.4%, and 
52.0 ± 3.0% at 1, 5, and 10 µM EGCG concentrations, 
respectively. Similarly, viability of HT-29 cells was 93.2 ± 
1%, 88.7 ± 0.9%, and 77.7 ± 1.9% at 10, 20, and 50 µM 
EGCG concentrations, respectively.
4. Discussion
Dietary components may play key roles in influencing 
DNA methylation status, resulting in regulation of gene 
expression. As cancer is a multistep process, gene activation 
and silencing throughout epigenetic mechanisms, as well 
as gene mutations, play important roles in carcinogenesis. 
In recent years, dietary components have been widely 
studied, and their potential use in cancer treatment and 
prevention strategies has been discussed (Li and Tollefsboy, 
2010; Hardy and Tollefsbol, 2011).
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Figure 1. Methylation-specific MLPA analysis of MCF-7 cells. X-axis shows tumor suppressor genes (1–25) and reference 
probes (26–40). Y-axis represents (A) copy number analysis of the tumor suppressor genes and (B) methylation profile of the 
tumor suppressor genes with respect to reference probes. The red line and blue line in panel A represent minimum normalized 
ratio with deletions and maximum normalized ratio with duplications in the regions, respectively. The red line and blue line in 
panel B represent minimum normalized ratio of unmethylated promoter regions and maximum normalized ratio of methylated 
regions, respectively. Promoter regions of CDH13, GATA5, and RARβ genes were hypermethylated in MCF-7 cell line.
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Figure 2. Methylation-specific MLPA analysis of HT-29 cells. X-axis shows tumor suppressor genes (1–25) and reference 
probes (26–40). Y-axis shows (A) copy number analysis of the tumor suppressor genes and (B) methylation profile of the 
tumor suppressor genes with respect to reference probes. The red line and blue line in panel A represent minimum normalized 
ratio with deletions and maximum normalized ratio with duplications in the regions, respectively. The red line and blue 
line in panel B represent minimum normalized ratio of unmethylated promoter regions and maximum normalized ratio of 
methylated regions, respectively. Promoter regions of RARβ, ESR1, PAX6, WT1, CADM1, CHFR, CDH13, and GATA5 genes 
were hypermethylated in HT-29 cell line.
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Figure 3. Effect of EGCG on the proliferation of MCF-7 and HT-29 cells after 48 
h. Cell proliferation data are expressed as the percentage of untreated cell controls. 
EGCG was more cytotoxic to MCF-7 cells (blue line) than HT-29 cells (red 
line). Error bars represent standard error of means obtained from independent 
triplicates.
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Promoter methylation is an important epigenetic 
change in cancer progression (Nystrom and Mutanen, 
2009). We found that CDH13, GATA5, and RARβ genes 
are methylated in the MCF-7 cell line: in addition to these 
genes, ESR1, PAX6, WT1, CADM1, and CHFR were also 
hypermethylated in HT-29 cell line. EGCG is known to 
be an inhibitor of DNMT1 enzyme activity. It has also 
been reported to be a chromatin remodeling agent (Li 
and Tollefsboy, 2010). Whenever EGCG inhibits DNMT1 
enzyme activity or affects chromatin remodeling in the 
promoter region of a gene, changes in gene expression 
occur, resulting in reactivation, as in the case of tumor 
suppressor genes. In this study, we investigated the 
demethylation effect of EGCG on the promoters of tumor 
suppressor genes in MCF-7 and HT-29 cell lines. 
Different EGCG concentrations did not change the 
methylation status of the promoter regions, suggesting 
that it has no demethylating effect on the cell lines 
studied. Various factors including target availability, 
intracellular bioavailability dependent on cellular uptake, 
biotransformation or efflux, and EGCG application 
concentration might contribute to the present results obtained 
from cells of different histological origin. Meanwhile, the 
presence or abundance of other DNA methyltransferases 
(DNMT3a and DNMT3b) might influence the demethylating 
effect of EGCG on these cell lines via DNMT1. It should be 
noted that DNMT1 activity assays using nuclear extracts 
and analysis of gene expression levels are needed for broader 
conclusions. Results of the present study demonstrated that 
EGCG was more cytotoxic to MCF-7 cells than HT-29, 
i.e. IC50 was approximately 10-fold higher in MCF-7 cells. 
Differences in intracellular signaling pathways between 
HT-29 and MCF-7 cells may affect the cytotoxic potency 
of EGCG since it binds to EGFR and PDGFR (Liang et al., 
1997; Sachinidis et al., 2000) and inhibits protein kinases 
(Chung et al., 1999, 2001). When studying cells of different 
histological origin, cytotoxic variations in response to test 
materials should be considered. We investigated the effect 
of EGCG on cell viability at different doses and found that 
the range of cell viability after all EGCG concentrations 
tested was 50%–92% and 78%–93% in MCF-7 and HT-29 
cell lines, respectively. However, we did not observe any 
changes in the DNA methylation status in the two cell lines 
after application of specified doses of EGCG. We conclude 
that the possible reasons are incubation doses that are below 
the DNMT1 inhibitory concentration or cell lines that are 
resistant to epigenetic effects of EGCG. In fact, according 
to previously reported data, nontoxic concentrations (<15% 
cell inhibition) of EGCG and catechin partially inhibited the 
methylation status of the promoter regions of the RARb gene 
(Lee et al., 2005) in breast cancer cells. In order to assess 
whether sublethal EGCG treatment may have caused the 
lack of demethylating effect on the cell lines tested, we also 
performed MS-MLPA analysis of MCF-7 cells treated with 
50 and 100 µM EGCG, at which 8% and 4% cell viability was 
attained, respectively. Similar to the results demonstrated, 
we did not observe any significant changes in the DNA 
methylation status of the treated cells at these concentrations 
(data not shown).
EGCG is transported into the cell by passive 
diffusion and converted to the methylated metabolites 
and glucuronides. However, EGCG is pumped out by 
multidrug resistance-associated proteins (MRPs), as 
evidenced by increased EGCG accumulation in HT-29 
cells in the presence of the MRP inhibitors indomethacin 
and probenecid (Hong et al., 2002). Both HT-29 and MCF-
7 cells were found to express MRP1 (Alvarez et al., 1998; 
Kars et al., 2006). 
In conclusion, although our study did not support the 
hypothesis that EGCG intake in early stages of colorectal 
and breast cancers could be preventive, especially when 
the importance of consuming dietary products in these 
tumors is taken into consideration, further studies could 
be designed on this basis with early-stage and numerous 
cancer cell lines. 
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